Biomedical Engineering Reference
In-Depth Information
13. Hearn WL, Rose S, Wagner J, Ciarleglio A, Mash DC (1991) Cocaethylene is more potent than
cocaine in mediating lethality. Pharmacol Biochem Behav 32(2):531-533
14. Hardman JG, Limbird LE (1996) Parmacological basis of therapeutics. Ninth Edition edn,
MCGrawHill
15. Logan BK (2002) Methamphetamine-effects on human performance and behavior. Forensic
Sci Rev 14:133-151
16. Battaglia G, Brooks BP, Kulsakdinum C, De Souza EB (1988) Pharmacologic profile of
MDMA (3,4-ethylenedioxymethamphetamine) at various brain recognition sites. Eur J
Pharmacol 149:159-163
17. Lora-Tamayo C, Tena T, Rodriguez A (1997) Amphetamine derivative related deaths. Forensic
Sci Int 85:149-157
18. Wright J, Cho AK, Gal J (1977) The metabolism of amphetamine in vitro by rabbit liver prepa-
rations: a comparison of R(−) and S(+) enantiomers. Xenobiotica 7(5):257-266
19. De la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J (2004)
Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug
Monit 26:137-144
20. Hoch PH, Cattell JP, Pennes HH (1952) Effects of mescaline and lysergic acid (d-lsd-25). Am
J Psychiatry 108:579-584
21. Friedhoff AJ, Goldstein M (1962) New developments in metabolism of mescaline and related
amines. N Y Acad Sci 96:5-13
22. Corelick DA, Balster RL (1995) Phencyclidine (PCP). In: Bloom EE, Kupfer DJ (eds)
Psychopharmacology: the fourth generation of progress. Raven Presi, New York
23. Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and
phencyclidine, selectively reduce excitation of central mammalian neurones by
N
-methyl-
aspartate. Br J Pharmacol 79(2):565-575
24. Uhl S, Schmid P, Schlatter C (1986) Pharmacokinetics of pentachlorophenol in man. Arch
Toxicol 58(3):182-186
25. Curran HV, Monaghan L (2001) In and out of the K-hole: a comparison of the acute and residual
effects of ketamine in frequent and infrequent ketamine users. Addiction 96:749-760
26. Koob GF (1992) Drugs of abuse: anatomy, pharmacology and function of reward pathways.
Trends Pharmacol Sci 13:77-185
27. Aps JK, Martens LC (2005) Review: the physiology of saliva and transfer of drugs into saliva.
Forensic Sci Int 150(2-3):119-131. doi
:
S0379-0738(05)00118-0 [pii] 10.1016/j.
28. Wille SM, Raes E, Lillsunde P, Gunnar T, Laloup M, Samyn N, Christophersen AS, Moeller
MR, Hammer KP, Verstraete AG (2009) Relationship between oral fluid and blood concentra-
tions of drugs of abuse in drivers suspected of driving under the influence of drugs. Ther Drug
Monit 31(4):511-519. doi
:
10.1097/FTD.0b013e3181ae46ea
29. Zuidema J, Hold KM, de Boer D, Maes RA (1996) Saliva as a specimen for therapeutic drug
monitoring in pharmacies. Pharm World Sci 18(6):193-194
30. Zuidema J, van Ginneken CA (1983) Clearance concept in salivary drug excretion. Part I:
theory. Pharm Acta Helv 58(3):88-93
31. Drummer OH (2005) Review: pharmacokinetics of illicit drugs in oral fluid. Forensic Sci Int
150(2-3):133-142. doi:
S0379-0738(05)00119-2 [pii] 10.1016/j.forsciint.2004.11.022
32. Hold KM, de Boer D, Zuidema J, Maes RAA (1996) Saliva as an analytical tool in toxicology.
Int J Drug Test 1:1-8
33. Toennes SW, Kauert GF, Steinmeyer S, Moeller MR (2005) Driving under the influence of
drugs - evaluation of analytical data of drugs in oral fluid, serum and urine, and correlation
with impairment symptoms. Forensic Sci Int 152(2-3):149-155. doi
:
S0379-0738(04)00443-8
34. Lim MD, Dickherber A, Compton CC (2011) Before you analyze a human specimen, think
quality, variability, and bias. Anal Chem 83(1):8-13. doi:
10.1021/ac1018974
35. Verstraete AG (2004) Detection times of drugs of abuse in blood, urine, and oral fluid. Ther
Drug Monit 26(2):200-205
